TG Therapeutics TGTX 深 沪
等待开盘 07-09 09:30:00 美东时间
56.60
-1.460
-2.51%
华盛通- 最 高58.47
- 今 开57.61
- 成交量 88.23万股
- 最 低 56.55
- 昨 收 58.06
- 总市值 866.45万
- 52周最高 58.50
- 市盈率 静 20.43
- 换手率 0.58%
- 52周最低 25.28
- 委 比 29.03%
- 总股本 0.00亿
- 历史最高 58.50
- 量 比 0.74
- 振 幅 3.31%
- 历史最低 0.9563
- 每 手 1
- 风险率 6.18%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 最高800美元！16家大行首予SpaceX"买入"或"超配"评级；奥本海上调康宁目标价从210美元升至230美元
今日重点评级关注：Canaccord Genuity：维持AtaiBeckley"买入"评级，目标价从15美元升至17美元；Truist Securities：维持NUVATION BIO"买入"评级，目标价从12美元升至13美元
07-08 15:31
美股大行评级 | 高盛上调AMD目标价从450美元升至640美元；伯恩斯坦上调阿斯麦目标价从1971美元升至2623美元
今日重点评级关注：Roth Capital：维持Nuvectis Pharma"买入"评级，目标价从20美元升至33美元；摩根士丹利：维持GXO Logistics"超配"评级，目标价从75美元升至78美元
07-07 11:34
HC Wainwright & Co. Reiterates Buy on TG Therapeutics, Maintains $70 Price Target
HC Wainwright & Co. analyst Emily Bodnar reiterates TG Therapeutics (NASDAQ:TGTX) with a Buy and maintains $70 price target.
07-07 00:41
TG Therapeutics initiates Phase 2 trial of Briumvi in treatment-resistant schizophrenia patients
TG Therapeutics initiates Phase 2 trial of Briumvi in treatment-resistant schizophrenia patients TG Therapeutics launched a Phase 2 trial of BRIUMVI in adults with treatment-resistant schizophrenia, marking an expansion beyond its multiple sclerosis franchise. Open-label, single-arm study targets ab
07-06 19:31
TG Therapeutics Stock Rises Thursday: What's Driving The Gains?
TG Therapeutics Inc. (NASDAQ:TGTX) shares are trading higher on Thursday as traders keep leaning into recent upbeat clinical updates around BRIUMVI. TG Therapeutics shares are advancing steadily. What’s pushing TGTX stock higher? What Is Driving TG Therapeutics’ Stock Today? TG Therapeutics reported...
06-19 03:29
Caseys General Stores Upbeat Q4 Earnings, Joins Applied Optoelectronics, Clover Health Investments And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were lower, with the Dow Jones index falling over 150 points on Wednesday. Shares of Caseys General Stores Inc (NASDAQ:CASY) rose sharply following strong quarterly earnings. For the fourth quarter, EPS were $4.37, exceeding the analyst estimate of $3.32 by 31.63%. Revenue for the quarte...
06-10 21:58
Why Is TG Therapeutics Stock Gaining Tuesday?
TGTX stock rises on positive Phase 1 data for subcutaneous BRIUMVI in myasthenia gravis. See what's next for TG Therapeutics.
06-09 23:17
TG Therapeutics Announces Pharmacokinetic, Pharmacodynamic, Safety, And Tolerability Data From Phase 1 Clinical Trial Evaluating Subcutaneous Formulation Of Ublituximab As Compared To IV BRIUMVI
Pharmacokinetic and pharmacodynamic data support quarterly subcutaneous BRIUMVI dosing regimen currently under evaluation in fully enrolled Phase 3 trial; Top-line Phase 3 data expected year-end 2026 or early
06-03 19:31
美股大行评级 | 潜在涨幅99.91%！Tigress Financial上调英伟达目标价至425美元，维持"强力买入"评级
今日重点评级关注：Tigress Financial：维持英伟达"强力买入"评级，目标价从360美元升至425美元；康托·菲茨杰拉德：维持DeFi Development"超配"评级，目标价从6美元升至7美元
05-28 19:00
TG Therapeutics To Highlight BRIUMVI Data In Adults With Relapsing Forms Of Multiple Sclerosis At 2026 CMSC Annual Meeting
TG Therapeutics, Inc. (NASDAQ:TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI® (ublituximab-xiiy) data in adults with relapsing forms of multiple sclerosis (RMS) at the 2026
05-26 19:33
